



US009486556B2

(12) **United States Patent**  
**Shi**

(10) **Patent No.:** **US 9,486,556 B2**  
(45) **Date of Patent:** **Nov. 8, 2016**

(54) **CONSISTENT CALCIUM CONTENT BONE ALLOGRAFT SYSTEMS AND METHODS**

(71) Applicant: **AlloSource**, Centennial, CO (US)

(72) Inventor: **Yaling Shi**, Larkspur, CO (US)

(73) Assignee: **AlloSource**, Centennial, CO (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/996,469**

(22) Filed: **Jan. 15, 2016**

(65) **Prior Publication Data**

US 2016/0129152 A1 May 12, 2016

**Related U.S. Application Data**

(62) Division of application No. 14/200,353, filed on Mar. 7, 2014, now Pat. No. 9,289,452.

(60) Provisional application No. 61/774,036, filed on Mar. 7, 2013.

(51) **Int. Cl.**

**A61K 35/32** (2015.01)

**A61L 27/36** (2006.01)

**A61L 27/38** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61L 27/3608** (2013.01); **A61K 35/32** (2013.01); **A61L 27/3834** (2013.01); **A61L 2430/02** (2013.01)

(58) **Field of Classification Search**

CPC ..... **A61K 35/32**; **A61L 2430/02**; **A61L 27/3608**

See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,627,853 A 12/1986 Campbell et al.

5,073,373 A 12/1991 O'Leary et al.

5,284,655 A 2/1994 Bogdanský et al.

5,314,476 A 5/1994 Prewett et al.

5,397,353 A 3/1995 Oliver et al.

5,405,390 A 4/1995 O'Leary et al.

5,439,684 A 8/1995 Prewett et al.

5,507,810 A 4/1996 Prewett et al.

5,507,813 A 4/1996 Dowd et al.

5,510,396 A 4/1996 Prewett et al.

(Continued)

**FOREIGN PATENT DOCUMENTS**

WO 2011019361 2/2011

WO 2012135205 10/2012

WO 2012142419 A1 10/2012

WO 2013047936 4/2013

WO 2014138612 4/2013

**OTHER PUBLICATIONS**

Extended European Search Report for European Patent Application No. 14759739.7, mailed on Jul. 15, 2016, all pages.

(Continued)

*Primary Examiner* — Ernst V Arnold


(74) *Attorney, Agent, or Firm* — Kilpatrick Townsend & Stockton LLP

(57)

**ABSTRACT**

Embodiments of the present invention provides bone graft compositions, and methods for their use and manufacture. A bone graft composition may include a first amount of non-demineralized cancellous bone. The composition may further include a second amount of demineralized cancellous bone. The composition may also include a third amount of demineralized cortical bone. The non-demineralized cancellous bone, the demineralized cancellous bone, and the demineralized cortical bone may be obtained from the same cadaveric donor.

**24 Claims, 4 Drawing Sheets**



(56)

## References Cited

## U.S. PATENT DOCUMENTS

5,531,791	A	7/1996	Wolfenbarger	8,202,539	B2	6/2012	Behnam et al.
5,676,146	A	10/1997	Scarborough	8,268,008	B2	9/2012	Betz et al.
5,707,962	A	1/1998	Chen et al.	8,292,968	B2	10/2012	Truncate et al.
5,749,874	A	5/1998	Schwartz	8,328,876	B2	12/2012	Behnam et al.
5,769,899	A	6/1998	Schwartz et al.	8,343,229	B2	1/2013	Coale
5,788,941	A	8/1998	Dalmaso et al.	8,389,017	B1	3/2013	Starling et al.
5,895,426	A	4/1999	Scarborough et al.	8,399,010	B2	3/2013	McKay
5,948,428	A	9/1999	Lee et al.	8,403,991	B2	3/2013	Ullrich, Jr. et al.
5,972,368	A	10/1999	McKay	8,409,623	B2	4/2013	Shim et al.
6,090,998	A	7/2000	Grooms et al.	8,435,566	B2	5/2013	Behnam et al.
6,180,606	B1	1/2001	Chen et al.	8,496,970	B2	7/2013	Binette et al.
6,189,537	B1	2/2001	Wolfenbarger	8,506,632	B2	8/2013	Ganem et al.
6,200,347	B1	3/2001	Anderson et al.	8,551,176	B2	10/2013	Ullrich, Jr. et al.
6,214,369	B1	4/2001	Grande	8,563,040	B2	10/2013	Marchosky
6,294,041	B1	9/2001	Boyce et al.	8,574,825	B2	11/2013	Shelby et al.
6,315,795	B1	11/2001	Scarborough et al.	8,585,766	B2	11/2013	Ullrich, Jr. et al.
6,340,477	B1	1/2002	Anderson	8,722,075	B2	5/2014	Shimp et al.
6,371,988	B1	4/2002	Pafford et al.	8,734,525	B2	5/2014	Behnam et al.
6,436,138	B1	8/2002	Dowd	8,771,368	B2	7/2014	McKay
6,464,983	B1	10/2002	Grotendorst	8,859,007	B2	10/2014	Carter et al.
6,478,825	B1	11/2002	Winterbottom et al.	8,992,964	B2	3/2015	Shelby et al.
6,482,231	B1	11/2002	Abatangelo	9,029,077	B2	5/2015	Song et al.
6,482,233	B1	11/2002	Aebi et al.	9,162,011	B2	10/2015	Stilwell et al.
6,511,509	B1	1/2003	Ford et al.	9,192,695	B2	11/2015	Shi
6,576,015	B2	6/2003	Geistlich et al.	9,289,452	B2	3/2016	Shi
6,616,698	B2	9/2003	Scarborough	2004/0043006	A1	3/2004	Badylak et al.
6,652,593	B2	11/2003	Boyer, II et al.	2004/0156834	A1	8/2004	Slavin et al.
6,685,626	B2	2/2004	Wironen	2007/0014729	A1	1/2007	Farhat et al.
6,696,073	B2	2/2004	Boyce et al.	2007/0020248	A1	1/2007	Everaerts et al.
6,716,245	B2	4/2004	Pasquet et al.	2007/0185231	A1	8/2007	Liu et al.
6,743,574	B1	6/2004	Wolfenbarger et al.	2008/0058953	A1	3/2008	Scarborough
6,746,484	B1	6/2004	Liu et al.	2008/0249632	A1	10/2008	Stone et al.
6,753,181	B2	6/2004	Atala	2008/0249638	A1	10/2008	Asgari
6,800,480	B1	10/2004	Bodnar et al.	2008/0286268	A1	11/2008	Johnson
6,805,713	B1	10/2004	Carter et al.	2008/0305145	A1	12/2008	Shelby et al.
6,855,169	B2	2/2005	Boyer et al.	2008/0306610	A1	12/2008	Wang et al.
6,902,578	B1	6/2005	Anderson et al.	2009/0053279	A1	2/2009	Badylak et al.
6,911,045	B2	6/2005	Shimp	2009/0155378	A1	6/2009	Behnam et al.
6,911,212	B2	6/2005	Gertzman et al.	2009/0202977	A1	8/2009	Ott et al.
7,018,412	B2	3/2006	Ferreira et al.	2010/0124776	A1	5/2010	Shi
7,048,765	B1	5/2006	Grooms et al.	2010/0168869	A1	7/2010	Long et al.
7,115,146	B2	10/2006	Boyer, II et al.	2010/0196333	A1	8/2010	Gaskins et al.
7,132,110	B2	11/2006	Kay et al.	2010/0241228	A1	9/2010	Syring et al.
7,163,691	B2	1/2007	Knaack et al.	2011/0070271	A1	3/2011	Truncate et al.
7,172,629	B2	2/2007	McKay	2012/0035276	A1	2/2012	Spievack
7,241,874	B2	7/2007	Thorne	2012/0082704	A1	4/2012	Phillips et al.
7,297,540	B2	11/2007	Mitrani	2012/0189707	A1	7/2012	Chun et al.
7,316,822	B2	1/2008	Binette et al.	2012/0213859	A1	8/2012	Shelby et al.
7,323,011	B2	1/2008	Shepard et al.	2012/0251609	A1	10/2012	Huang et al.
7,335,381	B2	2/2008	Malinin	2012/0259415	A1	10/2012	Van Dyke et al.
7,371,409	B2	5/2008	Petersen et al.	2013/0013068	A1	1/2013	Forsell et al.
7,498,040	B2	3/2009	Masinaei et al.	2013/0189338	A1	7/2013	Drapeau et al.
7,582,309	B2	9/2009	Rosenberg et al.	2013/0287741	A1	10/2013	Stilwell et al.
7,608,113	B2	10/2009	Boyer et al.	2014/0056865	A1	2/2014	Samaniego et al.
7,622,562	B2	11/2009	Thorne et al.	2014/0093543	A1	4/2014	Morreale
7,648,676	B2	1/2010	Mills et al.	2014/0121772	A1	5/2014	Emerton et al.
7,662,185	B2	2/2010	Alfaro et al.	2014/0170232	A1	6/2014	Shelby et al.
7,753,963	B2	7/2010	Boyer et al.	2014/0205674	A1	7/2014	Wei
7,785,634	B2	8/2010	Borden	2014/0208980	A1	7/2014	Song et al.
7,807,458	B2	10/2010	Schiller	2014/0212471	A1	7/2014	Drapeau et al.
7,811,608	B2	10/2010	Kay et al.	2014/0212499	A1	7/2014	Cooper et al.
7,815,926	B2	10/2010	Syring et al.	2014/0220142	A1	8/2014	Song et al.
7,837,740	B2	11/2010	Semler et al.	2014/0255506	A1	9/2014	Behnam et al.
7,875,296	B2	1/2011	Binette et al.	2014/0314822	A1	10/2014	Carter et al.
7,879,103	B2	2/2011	Gertzman et al.	2014/0342013	A1	11/2014	He et al.
7,883,511	B2	2/2011	Fernyhough	2015/0004247	A1	1/2015	Carter et al.
7,931,692	B2	4/2011	Sybert et al.	2015/0012107	A1	1/2015	Koford et al.
8,002,813	B2	8/2011	Scarborough et al.	2015/0174295	A1	6/2015	Woodell-May et al.
8,002,837	B2	8/2011	Stream et al.	2015/0182667	A1	7/2015	Guelcher et al.
8,025,896	B2	9/2011	Malaviya et al.	2015/0202345	A1	7/2015	Shelby et al.
8,039,016	B2	10/2011	Drapeau et al.	2015/0202346	A1	7/2015	Shelby et al.
8,137,702	B2	3/2012	Binette et al.	2015/0258244	A1	9/2015	Shelby et al.
8,163,549	B2	4/2012	Yao et al.				
8,167,943	B2	5/2012	Carter et al.				
8,197,474	B2	6/2012	Scarborough et al.				

## OTHER PUBLICATIONS

International Preliminary Report on Patentability for International Application No. PCT/US2014/021856 filed Mar. 7, 2014, mailed Sep. 17, 2015, 8 pages.

(56)

**References Cited**

**OTHER PUBLICATIONS**

Zimmer Dental, "Puros® Cortico-Cancellous Particulate Allograft"  
[Accessed on Nov. 3, 2015. Retrieved from the internet: [http://www.zimmerdental.com/Products/Regenerative/rg\\_puPuCorticoCancelPartAllogr.aspx](http://www.zimmerdental.com/Products/Regenerative/rg_puPuCorticoCancelPartAllogr.aspx)].

Zimmer Dental, "RegenaVate™ Demineralized Bone Matrix"  
[Accessed on Nov. 3, 2015. Retrieved from the internet: [http://www.zimmerdental.com/Products/Regenerative/rg\\_puRegenaVateDeminBoneMat.aspx](http://www.zimmerdental.com/Products/Regenerative/rg_puRegenaVateDeminBoneMat.aspx)].

Notice of Allowance mailed on Dec. 7, 2015 for U.S. Appl. No. 14/200,353, filed Mar. 7, 2014, all pages.




FIG. 1




FIG. 2





FIG. 3

**EXAMPLE 1**

0%	20%	50%	50%
	1 to 2 mm	1 to 4 mm	.5 to 4 mm (seeded)

**EXAMPLE 2**

0%	20%	50%	50%
	120 to 710 $\mu$ m	1 to 4 mm	.5 to 4 mm (seeded)

**FIG. 4**

1

## CONSISTENT CALCIUM CONTENT BONE ALLOGRAFT SYSTEMS AND METHODS

### CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 14/200,353 filed Mar. 7, 2014, which is a non-provisional of and claims the benefit of priority to U.S. Provisional Patent Application No. 61/774,036 filed Mar. 7, 2013, the entire contents of which are incorporated herein by reference for all purposes.

### BACKGROUND OF THE INVENTION

Embodiments of the present invention are directed in general to the field of medical grafts, and in particular to bone graft compositions, and methods of their use and manufacture.

Medical grafting procedures often involve the implantation of autogenous, allograft, or synthetic grafts into a patient to treat a particular condition or disease. The use of musculoskeletal allograft tissue in reconstructive orthopedic procedures and other medical procedures has markedly increased in recent years, and millions of musculoskeletal allografts have been safely transplanted. A common allograft is bone. Typically, bone grafts are reabsorbed and replaced with the patient's natural bone upon healing. Bone grafts can be used in a variety of indications, including neurosurgical and orthopedic spine procedures for example. In some instances, bone grafts can be used to fuse joints or to repair broken bones.

Allograft and autogenous bone are both derived from humans; the difference is that allograft is harvested from an individual (e.g. donor) other than the one (e.g. patient) receiving the graft. Allograft bone is often taken from cadavers that have donated their bone so that it can be used for living people who are in need of it, for example, patients whose bones have degenerated from cancer. Such tissues represent a gift from the donor or the donor family to enhance the quality of life for other people.

Hence, bone graft compositions and methods are presently available and provide real benefits to patients in need thereof. Yet many advances may still be made to provide improved bone graft systems and methods for treating patients. The bone graft systems and treatment and manufacture methods described herein provide further solutions and answers to these outstanding needs.

### BRIEF SUMMARY OF THE INVENTION

Bone is composed of organic and inorganic elements. By weight, bone is approximately 20% water. The weight of dry bone is made up of inorganic minerals such as calcium phosphate (e.g. about 65-70% of the weight) and an organic matrix of fibrous protein and collagen (e.g. about 30-35% of the weight). Both mineralized and demineralized bone can be used for grafting purposes.

Embodiments of the present invention encompass bone graft compositions containing mixtures of mineralized and demineralized bone, such that the compositions provide a bone allograft material having consistent calcium content, certain mechanical properties and handling characteristics, and desired biological activities.

In one aspect, embodiments of the present invention encompass composite bone graft materials, and methods for their use and manufacture. An exemplary method of manu-

2

facturing a composite bone graft material for administration to a treatment site of a human patient may include selecting a target calcium content or handling characteristic of the bone graft material, selecting a first amount of mineralized (i.e., non-demineralized) donor bone material, selecting a second amount of demineralized donor bone material, and combining the first and second amounts of bone material so as to obtain a bone graft composition having the target calcium content or handling characteristic. In these or other embodiments, the first amount of mineralized donor bone material may be selected based on the target calcium content or handling characteristic. Relatedly, the second amount of demineralized donor bone material may be selected based on the target calcium content or handling characteristic. In some instances, a ratio of the first amount of mineralized donor bone material to the second amount of demineralized donor bone material may be selected based on the target calcium content or handling characteristic. In some embodiments, the donor is an allogeneic cadaveric donor. In some embodiments, the composite bone graft material includes tissue obtained from the patient. In some embodiments, methods may also include combining adult mesenchymal stem cells with the bone material.

In another aspect, embodiments of the present invention may include a bone graft composition. The bone graft composition may include a first amount of non-demineralized cancellous bone, a second amount of demineralized cancellous bone, and a third amount of demineralized cortical bone. The non-demineralized cancellous bone, the demineralized cancellous bone, and the demineralized cortical bone may be obtained from the same cadaveric donor. Non-demineralized bone may be bone that has not contacted any acid and/or has not undergone either a complete or an incomplete demineralization process.

In some embodiments, the first amount of non-demineralized cancellous bone may have particles with sizes selected based on needs of the patient, needs of the physician, or for other reasons. Large particles may be difficult for a physician to handle or to mix. Examples of particle sizes may include between about 0.1 mm and about 9 mm, between about 2 mm and about 8 mm, between about 1 mm and about 7 mm, between about 1 mm and about 6 mm, between about 1 mm and about 5 mm, between about 0.1 mm and about 4 mm, between about 1 mm and about 4 mm, or between about 0.1 mm and about 1 mm in embodiments. The volume of the first amount may be chosen based on desired handling characteristics of the final product and/or the targeted calcium content. For example, the first amount may be between about 30% and about 70%, between about 40% and about 60%, between about 45% and about 55%, between about 48% and about 52%, between about 38% and about 42%, or about 50% of the volume of the bone graft composition. The non-demineralized cancellous bone in the first amount may have a calcium content selected based on handling characteristics or targeted calcium content. For example, the calcium content may be between about 20% and about 25%.

In some embodiments, the second amount of demineralized cancellous bone may include particles having sizes based on needs of the patient, needs of the physician, or for other reasons. Large particles may be difficult for a physician to handle or to mix. Examples of particle sizes may include between about 0.1 mm and about 9 mm, between about 2 mm and about 8 mm, between about 1 mm and about 7 mm, between about 1 mm and about 6 mm, between about 1 mm and about 5 mm, between about 0.1 mm and about 4 mm, between about 1 mm and about 4 mm, or between about 0.1



3

mm and about 1 mm, or between about 0.5 mm and about 4 mm in embodiments. The second amount of demineralized cancellous bone may include mesenchymal stem cells seeded to the surface of the demineralized cancellous bone. The volume of the second amount may be chosen based on desired handling characteristics of the final product and/or the targeted calcium content. For example, the second amount may be between about 30% and about 70%, between about 40% and about 60%, between about 45% and about 55%, between about 48% and about 52%, between about 38% and about 42%, or about 50% of the volume of the bone graft composition. The calcium content of the demineralized cancellous bone may be based on targeted calcium content or handling characteristics. For example, the calcium content may be between about 0% and about 8%, between about 0% and about 4%, between about 4% and about 6%, between about 0% and about 2%, or about 0% in embodiments.

In these or other embodiments, the third amount of demineralized cortical bone may have particle sizes selected based on needs of the patient, needs of the physician, or for other reasons. Small sizes may be easier for a physician to handle and may more easily fit inside cancellous bone material and not affect the volume of the final composition. For example, particles may have sizes between about 100  $\mu$ m and 2 mm, between about 1 mm and about 2 mm, between about 120  $\mu$ m and about 710  $\mu$ m, or between about 100  $\mu$ m and 1 mm. Smaller particles may increase biological activity. Cortical bone may contain growth factors, which may aid bone graft treatments. The volume of the third amount may be based on targeted calcium content, growth factor content, or handling characteristics. For example, the third amount may be between about 10% and about 40%, between about 10% and about 30%, between about 15% and about 25%, between about 19% and about 21%, or about 20% of the volume of the bone graft composition in embodiments. The calcium content of the demineralized cortical bone may be based on targeted calcium content or handling characteristics. For example, the demineralized cortical bone in the third amount may have a calcium content between about 0% and about 8%, between about 0% and about 4%, between about 4% and about 6%, between about 0% and about 2%, or about 0% in embodiments.

In these or other embodiments, the bone graft composition may have a calcium content between about 10% and about 19%, between about 10% and about 15%, between about 12% and about 17%, or about 15%. The calcium content of the bone graft composition may be measured by a residual calcium test or other known methods. The demineralized bone material may make up between about 25% and about 75%, between about 50% and about 75%, between about 40% and about 60%, or about 50% of the cancellous bone in the bone graft composition in embodiments. The remainder of the cancellous bone material may be non-demineralized bone material.

In another aspect, embodiments of the present invention may include a method of manufacturing a composite bone graft material for administration to a treatment site of a patient. The method may include selecting a target calcium content or handling characteristic of the composite bone graft material. In these or other embodiments, the method may include selecting a first amount of non-demineralized bone material from a donor, selecting a second amount of demineralized bone material from the donor, and combining the first and second amounts of bone material so as to obtain a bone graft composition having the target calcium content or handling characteristic. The target calcium content may

4

be between about 10% and about 19%, between about 10% and about 15%, between about 12% and about 17%, or about 15% in embodiments. The donor may be a cadaveric donor allogeneic to the patient. The method may include combining bone material from the patient with the first and second amounts of bone material from the donor.

In some embodiments, for the first amount, the non-demineralized bone material may include cancellous bone. The first amount of non-demineralized cancellous bone may have particles with sizes based on needs of the patient, needs of the physician, or for other reasons. Large particles may be more difficult for a physician to handle or to mix. Examples of particle sizes may include between about 0.1 mm and about 9 mm, between about 2 mm and about 8 mm, between about 1 mm and about 7 mm, between about 1 mm and about 6 mm, between about 1 mm and about 5 mm, between about 0.1 mm and about 4 mm, between about 1 mm and about 4 mm, or between about 0.1 mm and about 1 mm in embodiments. The volume of the first amount may be chosen based on desired handling characteristics of the final product or the targeted calcium content. For example, the first amount may be between about 30% and about 70%, between about 40% and about 60%, between about 45% and about 55%, between about 48% and about 52%, between about 38% and about 42%, or about 50% of the volume of the bone graft composition.

In these or other embodiments, for the second amount, the demineralized bone material may include cancellous bone. Particle sizes and volume percentages may be selected based on targeted calcium content or handling characteristics. Examples of particle sizes may include between about 0.1 mm and about 9 mm, between about 2 mm and about 8 mm, between about 1 mm and about 7 mm, between about 1 mm and about 6 mm, between about 1 mm and about 5 mm, between about 0.1 mm and about 4 mm, between about 1 mm and about 4 mm, or between about 0.1 mm and about 1 mm, or between about 0.5 mm and about 4 mm in embodiments. The second amount may be between about 30% and about 70%, between about 40% and about 60%, between about 45% and about 55%, between about 48% and about 52%, between about 38% and about 42%, or about 50% of the volume of the bone graft composition in embodiments.

In embodiments, the method may include selecting a third amount of demineralized donor material. The demineralized donor bone material may include cortical bone. Particles may have sizes between about 100  $\mu$ m and 2 mm, between about 1 mm and about 2 mm, between about 120  $\mu$ m and about 710  $\mu$ m, or between about 100  $\mu$ m and 1 mm. The volume of the third amount may be based on targeted calcium content, growth factor content, or handling characteristics. For example, the third amount may be between about 10% and about 40%, between about 10% and about 30%, between about 15% and about 25%, between about 19% and about 21%, or about 20% of the volume of the bone graft composition in embodiments. In these or other embodiments, combining the first and second amounts of bone material may include combining the third amount with the first and second amounts.

Prior to the combining step, the method may include seeding the mesenchymal stem cells onto the demineralized bone material. The method may include seeding a stromal vascular fraction onto the demineralized bone material, and the stromal vascular fraction may include mesenchymal stem cells and unwanted cells. In these or other embodiments, the method may include incubating the mesenchymal stem cells on the demineralized bone material for a period of

time to allow the mesenchymal stem cells to adhere to the demineralized bone material. The method may include rinsing the seeded demineralized bone material to remove the unwanted cells from the demineralized bone material.

In another aspect, embodiments of the present invention may include a method of treating a bone defect or other ailment in a patient. The method may include administering to the patient a bone graft composition that may include a first amount of non-demineralized cancellous bone, a second amount of demineralized cancellous bone, and a third amount of demineralized cortical bone. The non-demineralized cancellous bone, the demineralized cancellous bone, and the demineralized cortical bone may be obtained from the same cadaveric donor. The bone graft composition may be administered to treat spinal problems. With some spinal problems, the spine may need to be fused. In these or other embodiments, the bone graft composition may be placed in a spine cage, which may be placed between vertebrae. Additionally, the bone graft composition may be used to treat nonunions or critical size defects. In these or other embodiments, the bone graft composition may be applied or administered to the bone defect or surrounding bone.

In yet another aspect, embodiments of the present invention may include a method of manufacturing a composite bone graft material for administration to a treatment site of a patient. The method may include selecting a target calcium content or handling characteristic of the composite bone graft material. In these or other embodiments, the method may include selecting a first amount of non-demineralized bone material that includes cancellous bone from a donor. The first amount may have a first volume equal to about 50% of the composite bone graft material, and the first amount may include particles having sizes between about 0.1 mm and about 9 mm. The method may include selecting a second amount of demineralized bone material that contains cancellous bone from the donor. The second amount may have a second volume equal to about 50% of the composite bone graft material, and the second amount may have particles with sizes between about 0.1 mm and about 9 mm. In these or other embodiments, the method may include selecting a third amount of demineralized cortical bone, where the third amount may have a third volume equal to about 20% of the composite bone graft material. The method may include combining the first amount, second amount, third amount, and adult mesenchymal stem cells so as to obtain a bone graft composition having the target calcium content or handling characteristic.

The above described and many other features and attendant advantages of embodiments of the present invention will become apparent and further understood by reference to the following detailed description when considered in conjunction with the accompanying drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts aspects of bone graft systems and methods according to embodiments of the present invention.

FIG. 2 shows the steps in a method of manufacturing a composite bone graft material according to embodiments of the present invention.

FIG. 3 shows the steps in a method of treating a patient according to embodiments of the present invention.

FIG. 4 depicts aspects of bone graft systems and methods according to embodiments of the present invention.

#### DETAILED DESCRIPTION OF THE INVENTION

Embodiments of the present invention encompass bone graft compositions and methods for their use and manufac-

ture. Bone graft compositions as disclosed herein are provided with selected calcium content and/or handling characteristics. An exemplary manufacturing method may include selecting a target calcium content or handling characteristic of a bone graft composition, selecting a first amount of mineralized bone material, selecting a second amount of demineralized bone material, and combining the first and second amounts of bone material so as to obtain a bone graft composition having the target calcium content or handling characteristic.

#### Demineralization

Bone contains both mineralized and unmineralized components. For example the osteoid, which can be about 50% of the bone volume, is composed mainly of collagen. The mineralization of osteoid by inorganic mineral salts provides bone with its strength and rigidity. Bone contains several inorganic mineral components, such as calcium phosphate, calcium carbonate, magnesium, fluoride, sodium, and the like. Typical demineralization procedures involve removing such mineral components from bone. Any of a variety of techniques can be used to demineralize bone, including hydrochloric acid treatments, and the like. Demineralized bone matrix (DBM) refers to allograft bone that has had the inorganic mineral removed, leaving behind the organic collagen matrix. The American Association of Tissue Banks typically defines demineralized bone matrix as containing no more than 8% residual calcium as determined by standard methods. In this sense, a fully demineralized bone tissue can be considered to have no more than 8% residual calcium. It has been observed that cells such as mesenchymal stem cells may exhibit an affinity for adhering with demineralized bone.

#### Cortical Bone

Cortical bone, also known as compact bone, can be found in the outer shell portion of various bones. Cortical bone is typically, dense, hard, strong, and stiff. Cortical bone may include bone growth factors.

#### Cancellous Bone

Cancellous bone, also known as spongy bone, can be found at the end of long bones. Cancellous bone is typically less dense, softer, weaker, and less stiff than cortical bone.

#### Mineral Content of Bone

Cortical bone and cancellous bone can be harvested from a donor individual using standard techniques. The mineral or calcium content of the harvested bone may vary. In some cases, cortical bone is about 95% mineralized and cancellous bone is about 35-45% mineralized. In some cases, cortical bone is about 73.2 wt % mineral content, and cancellous bone is about 71.5 wt % mineral content. In some cases, the mineral content of the starting bone material is about 25%, prior to demineralization.

#### Composite Bone Materials

Embodiments of the present invention encompass bone materials containing various mixtures of mineralized (or non-demineralized bone) combined with demineralized bone. For example, bone compositions may include fully demineralized bone (e.g. cortical and/or cancellous) combined with non-demineralized bone (e.g. cortical and/or cancellous). Non-demineralized bone may be bone that has not undergone any demineralization, including treatment with acid. Demineralized and non-demineralized bone can be combined a certain ratios to provide bone allograft material having consistent calcium content and/or consistent handling characteristics.

Turning now to the drawings, FIG. 1 depicts aspects of bone composite systems and methods according to embodiments of the present invention. As shown here, as a typical

demineralization method proceeds, the amount of calcium in the bone is rapidly depleted. What is more, the acid concentration used, the duration of the demineralization process, and the process temperature are factors which can operate to impact the residual calcium content in the bone. Moreover, there may be variation in the bone density (e.g. due to donor age and/or bone location) as well as in the bone particle size. Hence, it may be difficult to accurately obtain a partially demineralized bone material having a calcium content which is within the specified range, or that is at a particular desired or selected value within the range.

Exemplary bone allograft compositions as disclosed herein contain a first amount of mineralized bone (A) and a second amount of demineralized bone (B). Hence, the bone allograft composition can have a consistent calcium content. Typically, the demineralized bone is provided as a demineralized bone matrix, or allograft bone which has had inorganic mineral removed, leaving behind the organic collagen matrix. As a result of the demineralization process, the DBM is more biologically active (e.g. BMPs were activated during demineralization process) than non-demineralized bone grafts. Conversely the mechanical or structural integrity properties of demineralized bone may be significantly diminished as compared to mineralized bone.

Typically, cortical bone and cancellous bone are separated from one another, and then demineralized. For example, the cortical bone and cancellous bone can be demineralized in separate batches.

FIG. 2 shows the steps in a method 200 according to embodiments of the present invention. The method 200 may include selecting a target calcium content or handling characteristic 202. The method 200 may include selecting a first amount of bone material 204. In these or other embodiments, the bone material may be non-demineralized bone material from a donor. The method 200 may include selecting a second amount of bone material 206. In some cases, the second amount of bone material may include demineralized bone material. The method 200 may include combining the first and second amounts 208. By combining mineralized and demineralized bone material, it is possible to obtain a resulting mixture having desirable handling characteristics, calcium content, and BMP activity.

In some embodiments, particles sizes and/or volume percentages of components of the bone graft composition may be selected based on handling characteristics of the bone graft composition. Such handling characteristics may include compressibility and cohesion characteristics. Compressibility characteristics for bone graft compositions may include whether the composition is more like sand or more like a sponge. Cohesion characteristics for bone graft compositions may include compositions whether the composition sticks together or does not stick together. Compositions that are more like sand and do not stick together may be difficult for a physician to handle and administer to only the treatment site. Product that is too spongy may be harder for physicians to apply in consistent amounts across different treatments in part because in some instances, a physician may compress the spongy product more than in other instances.

In some cases, composite materials may include components which are present in an amount that is within a volume percentage range. For example, demineralized cancellous bone may be present within a range between about 30% and about 70%, between about 40% and about 60%, between about 45% and about 55%, between about 48% and about 52%, or about 50%. The non-demineralized cancellous bone may be present within a range between about 30% and about

70%, between about 40% and about 60%, between about 45% and about 55%, between about 48% and about 52%, or about 50%. The demineralized cortical bone may be present within a range between about 10% and about 40%, between about 10% and about 30%, between about 15% and about 25%, between about 19% and about 21%, or about 20%. Such volumes may be based on the volume of the bone graft composition product.

The cancellous particles may be more sponge-like and the cortical bone material may reside within spaces of the sponge-like cancellous particles. Hence, the sum of the starting volume amounts may exceed 100% of the final volume of the composite bone material. According to some embodiments, the volume of the final composition may largely be determined by the volumes of demineralized and non-demineralized cancellous components. Hence, a 40 ml volume of demineralized cancellous bone combined with a 40 ml volume of non-demineralized cancellous bone and a 20 ml volume of demineralized cortical bone may provide a composition having a final volume of 80 ml.

In an exemplary embodiment, a composite bone material may have a calcium content within a range from about 10% to about 15%. In these or other embodiments, the bone graft composition may have a calcium content between about 10% and about 19%, between about 12% and about 17%, or about 15%. In some cases, an amount of mineralized cancellous bone present in the composite bone material may have a calcium content of about 20%. In some cases, an amount of demineralized cancellous bone present in the composite bone material may have a calcium content within a range from about 0% (or undetected) to about 8%. In some cases, an amount of mineralized cortical bone present in the composite bone material may have a calcium content of about 25%. In some cases, an amount of cortical demineralized bone present in the composite bone material may have a calcium content within a range from about 0% (or undetected) to about 8%.

Examples of particle sizes of cancellous bone material may include between about 0.1 mm and about 9 mm, between about 2 mm and about 8 mm, between about 1 mm and about 7 mm, between about 1 mm and about 6 mm, between about 1 mm and about 5 mm, between about 0.1 mm and about 4 mm, between about 1 mm and about 4 mm, or between about 0.1 mm and about 1 mm, or between about 0.5 mm and about 4 mm in embodiments. Examples of particle sizes of cortical bone may include between about 100  $\mu$ m and 2 mm, between about 1 mm and about 2 mm, between about 120  $\mu$ m and about 710  $\mu$ m, or between about 100  $\mu$ m and 1 mm. Smaller particle sizes, including those of cortical bone material, may result in more BMPs being activated. Particle sizes may be obtained using a series of sieves to remove particles smaller and larger than a desired range.

According to some embodiments, instead of adding a patient's own cancellous bone material to an implant graft composition to treat a fracture or other bone defect during a surgical procedure, it is possible to use non-demineralized cancellous bone in a composite bone material as discussed elsewhere herein.

In some cases, the composite bone material will include bone obtained from an allogeneic donor. In some cases, both the demineralized and the mineralized components can be harvested from a common donor and combined to provide the composite bone material. Relatedly, the composite bone material can include cells (e.g. adult mesenchymal stem cells) obtained from the same donor. In some cases, the composite bone material may include bone obtained from a

recipient patient. Hence, a composite bone material may include autologous demineralized and/or mineralized bone.

In some embodiments, methods of manufacturing composite bone graft material may include seeding demineralized bone material with a stromal vascular fraction. The stromal vascular fraction may be formed by digesting adipose tissue. Digesting the adipose tissue may include making a collagenase I solution and filtering the solution, and mixing the adipose solution with the collagenase solution. The adipose solution with the collagenase I solution may be agitated in a shaker flask. This may provide the adipose tissue with a visually smooth appearance. The method may include aspirating a supernatant containing mature adipocytes so as to provide a pellet that is the stromal vascular fraction.

The stromal vascular fraction may include mesenchymal stem cells and other cells, which may be unwanted or unneeded in embodiments of the invention. Unwanted cells may include hematopoietic stem cells and other stromal cells. In these or other embodiments, methods may include incubating the mesenchymal stem cells on the demineralized bone material for a period of time to allow the mesenchymal stem cells to adhere to the demineralized bone material. Methods may include rinsing the seeded demineralized bone material to remove all, substantially all, or a portion of the unwanted cells from the demineralized bone material in embodiments. Methods involving mesenchymal stem cells may be as disclosed in Ser. No. 12/612,583 filed Nov. 4, 2009 and U.S. Provisional Patent Application No. 61/790,412 filed Mar. 15, 2013, the entire content of both is incorporated herein by reference for all purposes.

In some cases, the bone graft composition may be administered to a patient as a flowable, syringeable, putty-like material. For example, a putty-like moldable matrix can be delivered through a cannula or other syringe attachment to a treatment site. Such bone matrix compositions may be used as how soft tissue matrix compositions are used and formed in U.S. patent application Ser. No. 13/712,295 filed Dec. 12, 2012, the entire content of which is incorporated herein by reference for all purposes. In some cases, the bone material and/or mesenchymal stem cells may be present in a morselized form. Hence, compositions and methods as disclosed herein may include a soft tissue or skin matrix material combined with stem cell morsels, so as to form a bone putty. A putty formulation may have good handling characteristics. For example, such morsels or putty compositions may stay in place upon implantation. Relatedly, such morsels or putty compositions may persist at the site of the application (e.g., bone defect area) and resist removal by irrigation and/or contact with blood. In some instances, flowable decellularized skin or de-epidermized skin (or other soft tissue) can provide and effective carrier to hold demineralized bone material and/or mesenchymal stem cells in place and prevent their migration.

Embodiments of the present invention may encompass delivering the bone graft composition combined with a carrier to a treatment site of the patient. In some cases, the carrier is derived from a human donor and includes an organic phase of a decellularized adipose tissue that has been exposed to alkaline organic solution. Such methods and compositions may be similar to those taught in U.S. patent application Ser. No. 13/970,324 filed Aug. 19, 2013, the entire content of which is incorporated herein by reference for all purposes. In these or other embodiments, methods may include administering treatment material combined with a matrix to a treatment site of a patient. The matrix may include a processed organic phase of decellularized adipose

tissue that is substantially free of a stromal vascular fraction. In some cases, the adipose component includes an adipose derived carrier.

FIG. 3 shows a method 300 of treating a bone defect in a patient according to embodiments. The method 300 may include providing a bone graft composition 302. In these or other embodiments, the bone graft composition may include any of the bone graft compositions described herein. The method 300 may include administering the bone graft composition to the patient 304.

#### Example 1

In one example (FIG. 4), a composite bone material includes 50% fully demineralized cancellous bone (e.g. 0.5 mm to 4 mm particle size) seeded with cells (e.g. adult mesenchymal stem cells), 50% non-demineralized cancellous bone (e.g. 1 mm to 4 mm particle size), and 20% fully demineralized cortical bone (e.g. 1 mm to 2 mm particle size). Particle size ranges may be obtained by using two sieves to separate out ground bone material. According to some embodiments, the fully demineralized cortical bone may not contribute toward the final volume of the composite bone material, because the particle size is relatively small and can fill into pores of the larger cancellous particles.

#### Example 2

In another example (FIG. 4), a composite bone material includes 50% fully demineralized cancellous bone (e.g. 0.5 mm to 4 mm particle size) seeded with cells (e.g. adult mesenchymal stem cells), 50% non-demineralized cancellous bone (e.g. 1 mm to 4 mm particle size), and 20% fully demineralized cortical bone (e.g. 120  $\mu$ m to 710  $\mu$ m particle size). According to some embodiments, the fully demineralized cortical bone may not contribute toward the final volume of the composite bone material, because the particle size is relatively small and can fill into pores of the larger cancellous particles.

In each of these examples, it was observed that the allograft material exhibited consistent and satisfying handling characteristics. Hence, by combining a fully demineralized bone material (e.g. DBM) with a non-demineralized bone matrix material, it is possible to create a very consistent partially demineralized bone product, which may otherwise be difficult to produce using traditional demineralization approaches. Relatedly, the product can have a consistent calcium content.

Table 1 describes certain characteristics of various composite bone material formulations according to embodiments of the present invention. Each of the formulations in Table 1 includes 20% by volume of demineralized cortical bone.

TABLE 1

Ratio in product: demineralized cancellous bone to non-demineralized cancellous bone	Calcium content in product (e.g. amount of calcium present in mixture)	Handling Characteristics of product (description)
0:1 (0% demin)	25%	Hard sand like particles, does not stick together well
1:4 (25% demin)	19%	Sand like particles, does not stick together well
1:1 (50% demin)	15%	Sticks together very well, not too hard, not too spongy

TABLE 1-continued

Ratio in product: demineralized cancellous bone to non-demineralized cancellous bone	Calcium content in product (e.g. amount of calcium present in mixture)	Handling Characteristics of product (description)
3:4 (75% demin)	10%	Sticks together well, slightly spongy
1:0 (100% demin)	less than 8%	Does not stick together well, very spongy

According to some embodiments, bone graft material can be demineralized for 60 minutes in 1 N HCl during the process. To evaluate residual calcium content, samples of the morselized bone product were subjected to inductively coupled plasma spectroscopy analysis by SunLabs (Tampa, Fla.). The resulting residual calcium was 1.0%. Each value is well below the 8.0% residual calcium required by AATB to claim full demineralization.

To evaluate certain characteristics of composite bone material, samples were manipulated by hand. For example, by squeezing or holding the material in the hand, it is possible to observe adhesion characteristics, for example by noting the extent to which the material sticks to one's fingers when extending the fingers. Similarly, by squeezing or holding the material in the hand, it is possible to observe cohesion characteristics, for example by noting the extent to which the material tends to adhere to itself. Further, by squeezing or holding the material in the hand, it is possible to observe compressibility characteristics, for example by noting the extent to which the material can be compressed. What is more, by squeezing or holding the material in the hand, it is possible to observe abrasiveness characteristics, for example by noting the shape and/or hardness of particles present in the material.

When referring to the calcium content in the product, there may be various types of calcium, such as calcium phosphate, calcium carbonate, and the like. For example, some bone material is formed mostly of calcium phosphate in the chemical arrangement termed calcium hydroxylapatite.

All patents, patent publications, patent applications, journal articles, books, technical references, and the like discussed in the instant disclosure are incorporated herein by reference in their entirety for all purposes.

It is to be understood that the figures and descriptions of the invention have been simplified to illustrate elements that are relevant for a clear understanding of the invention. It should be appreciated that the figures are presented for illustrative purposes and not as construction drawings. Omitted details and modifications or alternative embodiments are within the purview of persons of ordinary skill in the art.

It can be appreciated that, in certain aspects of the invention, a single component may be replaced by multiple components, and multiple components may be replaced by a single component, to provide an element or structure or to perform a given function or functions. Except where such substitution would not be operative to practice certain embodiments of the invention, such substitution is considered within the scope of the invention.

The examples presented herein are intended to illustrate potential and specific implementations of the invention. It can be appreciated that the examples are intended primarily for purposes of illustration of the invention for those skilled in the art. There may be variations to these diagrams or the

operations described herein without departing from the spirit of the invention. For instance, in certain cases, method steps or operations may be performed or executed in differing order, or operations may be added, deleted or modified.

Different arrangements of the components depicted in the drawings or described above, as well as components and steps not shown or described are possible. Similarly, some features and sub-combinations are useful and may be employed without reference to other features and sub-combinations. Embodiments of the invention have been described for illustrative and not restrictive purposes, and alternative embodiments will become apparent to readers of this patent. Accordingly, the present invention is not limited to the embodiments described above or depicted in the drawings, and various embodiments and modifications can be made without departing from the scope of the claims below.

Where a range of values is provided, it is understood that each intervening value, to the smallest fraction of the unit of the lower limit, unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Any narrower range between any stated values or unstated intervening values in a stated range and any other stated or intervening value in that stated range is encompassed. The upper and lower limits of those smaller ranges may independently be included or excluded in the range, and each range where either, neither, or both limits are included in the smaller ranges is also encompassed within the technology, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included.

What is claimed is:

1. A bone graft composition, comprising:

- a first amount of non-demineralized cancellous bone;
- a second amount of demineralized cancellous bone, wherein the second amount comprises between about 50% and about 75% of the volume of the bone graft composition; and
- a third amount of demineralized cortical bone, wherein the non-demineralized cancellous bone, the demineralized cancellous bone, and the demineralized cortical bone are obtained from the same cadaveric donor, wherein:
  - the calcium content of the bone graft composition is between about 10% and about 15%.

2. The bone graft composition according to claim 1, wherein the second amount of demineralized cancellous bone comprises mesenchymal stem cells seeded to the surface of the demineralized cancellous bone.

3. The bone graft composition according to claim 1, wherein the demineralized cortical bone comprises particles having sizes between about 1 mm and about 2 mm.

4. The bone graft composition according to claim 1, wherein:

- the non-demineralized cancellous bone comprises particles having sizes between about 1 mm and about 4 mm,
- the demineralized cancellous bone comprises particles having sizes between about 0.5 mm and about 4 mm, and
- the demineralized cortical bone comprises particles having sizes between about 120  $\mu$ m and about 710  $\mu$ m.

5. The bone graft composition according to claim 1, wherein:

- the first amount is about 50% of the volume of the bone graft composition, and

**13**

the second amount is about 50% of the volume of the bone graft composition.

6. The bone graft composition according to claim 1, wherein the third amount is between about 19% and about 21% of the volume of the bone graft composition.

7. The bone graft composition according to claim 1, wherein the second amount comprises particles having sizes between about 0.5 mm and about 4 mm.

8. The bone graft composition according to claim 1, wherein the second amount comprises particles having sizes between about 1 mm and about 2 mm.

9. The bone graft composition according to claim 1, wherein the third amount comprises particles having sizes between about 120  $\mu\text{m}$  and about 710  $\mu\text{m}$ .

10. The bone graft composition according to claim 1, wherein the first amount comprises between about 25% and about 50% of the final volume of the bone graft composition.

11. The bone graft composition according to claim 1, wherein the third amount comprises about 20% of the final volume of the bone graft composition.

12. The bone graft composition according to claim 1, wherein:

the first amount comprises about 50% of the final volume of the bone graft composition,  
the second amount comprises about 50% of the final volume of the bone graft composition, and  
the third amount comprises about 20% of the final volume of the bone graft composition.

13. A method of treating a bone defect in a patient, the method comprising administering to the patient a bone graft composition comprising:

a first amount of non-demineralized cancellous bone;  
a second amount of demineralized cancellous bone, wherein the second amount comprises between about 50% and about 75% of the volume of the bone graft composition; and  
a third amount of demineralized cortical bone, wherein the non-demineralized cancellous bone, the demineralized cancellous bone, and the demineralized cortical bone are obtained from the same cadaveric donor, wherein:  
the calcium content of the bone graft composition is between about 10% and about 15%.

14. The method according to claim 13, wherein the second amount of demineralized cancellous bone comprises mesenchymal stem cells seeded to the surface of the demineralized cancellous bone.

**14**

15. The method according to claim 13, wherein the demineralized cortical bone comprises particles having sizes between about 1 mm and about 2 mm.

16. The method according to claim 13, wherein:

the non-demineralized cancellous bone comprises particles having sizes between about 1 mm and about 4 mm,

the demineralized cancellous bone comprises particles having sizes between about 0.5 mm and about 4 mm, and

the demineralized cortical bone comprises particles having sizes between about 120  $\mu\text{m}$  and about 710  $\mu\text{m}$ .

17. The method according to claim 13, wherein:

the first amount is about 50% of the volume of the bone graft composition, and

the second amount is about 50% of the volume of the bone graft composition.

18. The method according to claim 13, wherein the third amount is between about 19% and about 21% of the volume of the bone graft composition.

19. The method according to claim 13, wherein the second amount comprises particles having sizes between about 0.5 mm and about 4 mm.

20. The method according to claim 13, wherein the second amount comprises particles having sizes between about 1 mm and about 2 mm.

21. The method according to claim 13, wherein the third amount comprises particles having sizes between about 120  $\mu\text{m}$  and about 710  $\mu\text{m}$ .

22. The method according to claim 13, wherein the first amount comprises between about 25% and about 50% of the final volume of the bone graft composition.

23. The method according to claim 13, wherein the third amount comprises about 20% of the final volume of the bone graft composition.

24. The method according to claim 13, wherein:

the first amount comprises about 50% of the final volume of the bone graft composition,  
the second amount comprises about 50% of the final volume of the bone graft composition, and  
the third amount comprises about 20% of the final volume of the bone graft composition.

\* \* \* \* \*